Shanghai Fosun Pharmaceutical's holding subsidiary, the injection of ibuprofen lysine, has obtained registration approval.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., has recently obtained approval from the National Medical Products Administration for the drug registration application of Flurbiprofen Sodium Injection. The approved indication for this drug is postoperative and cancer pain relief. This drug is a chemically developed product by the group. As of March 2026, the group's cumulative research and development investment for this drug is approximately RMB 34 million (unaudited).